Morning Buzz: Vascular Biogenics (VBLT), Genetic Technologies (GENE), Apple Inc. (AAPL), Celsus Therapeutics (CLTX)

Vascular Biogenics Ltd. (VBLT) is seeing a notable downward move in pre-market trading after the company announced that its phase 2 studies of VB-201 in patients with psoriasis and Ulcerative Colitis did not meet primary endpoints. Biogenics said it does not plan to continue development of VB-201 in these indications. “We are disappointed by the […] View the full post at: Morning Buzz: Vascular Biogenics (VBLT), Genetic Technologies (GENE), Apple Inc. (AAPL), Celsus Therapeutics (CLTX) Related posts: iPhone Going to Russia Harbinger Discloses 9.48% Stake in Palm (PALM)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.